

# A Comparative Histological Study on the Effect of Adipose-Derived Stem Cells versus Their Conditioned Medium on Indomethacin Induced Enteritis in Adult Female Albino Rats

**Original Article** *<sup>1</sup>Abeer F. Abdel Mohsen, <sup>1</sup>Nagla M. Salama, <sup>2</sup>Laila A. Rashed, <sup>1</sup>Eman A. Farag and <sup>1</sup>Asmaa M. Abdel Hameed*

*<sup>1</sup>Histology Department, <sup>2</sup>Biochemistry Department, Faculty of Medicine Cairo University, Cairo, Egypt*

## ABSTRACT

**Background:** Inflammatory bowel disease (IBD), including Crohn's disease (CD), is a chronic complex immune-inflammatory disorder with increasing prevalence and inadequate conventional treatment.

**Aim of work:** Evaluating the therapeutic effect of adipose-derived mesenchymal stem cells (ADSCs) versus ADSC-conditioned medium (CM) in a rat model of enteritis (CD).

**Materials and Methods:** Fifty-six female albino rats were used, 16 rats served as control (group I). In the remaining 40 rats, enteritis was induced by SC injection of 2 doses of indomethacin 7.5 mg/kg, on days 0 and 1 of the experiment. After 10 days, rats were divided equally into 5 groups: Groups II and III received no further treatment and sacrificed at days 10 and 24 respectively. Groups IV, V and VI with ADSCs ( $1 \times 10^6$  cells, IV single dose), ADSC-CM (0.5ml intraperitoneal (IP), 5 doses) and DMEM (0.5ml IP, 5 doses) respectively; they were all sacrificed at day 24. Ileum specimens were stained with H&E, Masson's trichrome and Alcian blue/ PAS stains as well as MMP1 and PCNA immunostains. Morphometric measurements of area % of collagen and MMP1, number of goblet cells and PCNA positive cells as well as optical density of Alcian blue/ PAS reaction were taken and statistically analyzed.

**Results:** Groups II, III and VI revealed obvious damage of villi and crypts, desquamation of epithelium, oedema and obvious mononuclear cellular infiltration together with significant decrease in number of goblet cells and PCNA +ve cells as well as in the optical density of Alcian blue/ PAS reaction and significant increase in the area % of collagen (in groups III and VI) and MMP1 as compared to control. Groups IV and V nearly regained the normal histological structure of villi and crypts.

**Conclusion:** ADSC-CM was as effective as ADSCs in reducing tissue fibrosis and in enhancing proliferation and mucosal regeneration in a rat model of enteritis (CD).

**Received:** 10 July 2018, **Accepted:** 29 August 2018

**Key Words:** ADSCs, conditioned medium, crohn's disease, enteritis, indomethacin.

**Corresponding Author:** Asmaa M. Abdel Hameed, MSc., Department of Histology, Faculty of Medicine, Cairo University, Egypt, Tel.: +20 1090304335, **E-mail:** alabd.alsaleh@yahoo.com

**ISSN:** 1110-0559, Vol. 41, No. 4

## INTRODUCTION

Inflammatory bowel disease is a chronic complex pathological immuno-inflammatory response with increasing prevalence. It is a consequence of the improper and continuous activation of the mucosal immune system sustained by physiological flora<sup>[1]</sup>. CD is a major type of IBD that affects any part of the gastrointestinal tract (GIT), especially the terminal ileum. It has chronic progressive course which may lead to stricturing and bowel fistula with frequent terminal need for intestinal resection<sup>[2]</sup>. The current guidelines for conventional IBD therapy recommend the use of aminosalicylates, corticosteroids, or immunosuppressive drugs to treat symptoms and to prevent relapses<sup>[3]</sup>. However, these therapies exhibit inadequacies

in efficacy and have many side effects, especially with the use of immunosuppressants<sup>[4]</sup>. Accumulating evidence in animal and human studies has demonstrated that Mesenchymal stem cells (MSCs) may be used for the IBD treatment due to its immunomodulatory properties<sup>[5,6]</sup>.

Application of ADSCs is a novel approach for enhancing regeneration or repair of damaged tissues particularly in an environment which is unfavorable for wound healing as Crohn's-related rectovaginal or perianal fistula. It has been hypothesized that the therapeutic effect of ADSCs may be due to their immunoregulatory and anti-inflammatory properties, which may work together to accelerate healing<sup>[7]</sup>. Although application of MSCs has shown beneficial effects in the therapy of autoimmune and chronic

inflammatory diseases, the clinical application of stem cells still raises numerous ethical and safety concerns with the ability to promote tumor growth and metastasis and overestimated therapeutic potential of MSCs. Thus, there is a strong need for more safe approaches to be used in the disease management<sup>[8]</sup>. MSCs can modulate inflammation and promote the regeneration of injured tissues through the secretion of factors that is called CM rather than by direct engraftment and differentiation<sup>[9]</sup>. The Mesenchymal stem cell-conditioned medium (MSC-CM) contains different kinds of cytokines and growth factors that have anti-inflammatory, immune regulation and stimulating regeneration effects. Thus, it may be a promising alternative to the direct administration of MSCs<sup>[10]</sup>. The aim of this study was to develop an experimental model of enteritis (Crohn's disease) using indomethacin in adult female albino rat. On such model, the possible therapeutic regenerative effect of both ADSCs and their conditioned medium was evaluated and compared. This was achieved by histological, immunohistochemical and morphometric studies.

## MATERIALS AND METHODS

### I) Animals:

Fifty six female albino rats (190- 200 gm) were treated according to Cairo University Animal Use Committee guidelines. They were housed at the animal house, Faculty of Medicine, bred in wire mesh cages at and normal light/dark cycle and provided with ordinary rat chow with free water and food access. The start of the study was designed as day 0.

### II) Experimental design:

#### The rats were divided into 5 groups:

Group I (control group, 16 rats): received SC injection of 0.06ml of saline on two consecutive days 24h apart (days 0 and 1) and left till day 10. The rats were divided into 4 subgroups (4 rats each):

**Subgroup IA:** served as control for group II. Rats were sacrificed at day 10.

**Subgroup IB:** served as control for group III, were left without further treatment. They were sacrificed at day 24.

**Subgroup IC:** served as control for group IV, were injected at day 10 with 0.1ml PBS via the tail vein. They were sacrificed at day 24.

**Subgroup ID:** served as control for groups V and VI, were injected IP with 0.5ml Dulbecco's modified Eagle's medium (DMEM) for 5 consecutive days (days 10-14). They were sacrificed at day 24.

#### Induction of enteritis model:

Forty rats were injected SC with indomethacin (Liomethacin; in the form of powder 50 mg dissolved in 2ml saline) at a dose of 7.5 mg/kg (i.e 1.5mg indomethacin dissolved in 0.06ml saline/rat), two doses 24h apart

(days 0 and 1)<sup>[11]</sup>. They were then left for 10 days and at day 10 they were divided into 5 groups:

Group II (Indomethacin induced enteritis, 8 rats): sacrificed at day 10.

Group III (Recovery group, 8 rats): rats were left without further treatment, the rats were sacrificed at day 24.

Group IV (Stem cell-treated group, 8 rats): rats were injected at day 10 with  $1 \times 10^6$  cells/0.5 ml PBS (PBS, GIBCO, NY, USA) IV via the tail vein<sup>[12]</sup>. The rats were sacrificed at day 24<sup>[13]</sup>.

Group V (ADSC-CM-treated group, 8 rats): rats were injected IP with 0.5ml of "culture CM after interferon gamma (IFN ) stimulation"/ day for five consecutive days (days 10-14)<sup>[14]</sup>. The rats were sacrificed at day 24.

Group VI (DMEM treated group): rats were injected IP with 0.5ml of DMEM/day for five consecutive days (days 10-14). The rats were sacrificed at day 24.

Body weight of the rats was recorded at days 0, 10 and 24. The change in stool consistency, presence of blood in stool and increase the frequency (as determined by the need to change the animal cage) were observed.

At the end of experiment, the rats were sacrificed under anaesthesia by IP injection of ketamine (90 mg/kg)/xylazine (15 mg/kg)<sup>[15]</sup>. A midline abdominal incision was made and the abdomen was opened. The small intestine was dissected and the ileum (a segment about 1.5cm proximal to the cecum) was excised. The specimens were fixed in 10% buffered formalin solution for 24 hours, dehydrated in ascending grades of ethanol and embedded in paraffin. Serial sections of 7  $\mu$ m thickness were cut and subjected to the followings:

1. Fluorescent microscope for detection of PKH26-labeled ADSCs in unstained sections<sup>[16]</sup>
2. Hematoxylin and eosin (HandE) stain<sup>[17]</sup>
3. Masson's trichrome stain for demonstration of collagen fibres<sup>[18]</sup>
4. Alcian blue / Periodic acid Schiff's (PAS) stain for demonstration of mucus in goblet cells<sup>[17]</sup>
5. Immunohistochemical staining<sup>[19]</sup> for matrix metalloproteinase 1 (MMP1). (Rabbit monoclonal primary antibody Novusbiologicals Corporation, CA, USA, Catalog Number: 110-57211) It is one of intestinal proteases that indicates excessive degradation of extracellular matrix (ECM)<sup>[20]</sup>
6. Immunohistochemical staining<sup>[19]</sup> for proliferating cell nuclear antigen (PCNA) (Mouse monoclonal antibody IHC World Corporation, CA, USA, Catalog Number: SC-56) as a marker of cell proliferation<sup>[21]</sup>

The sections for immunohistochemical stains were boiled for 10 min in 10 mM citrate buffer (AP9003) at pH 6 for antigen retrieval then incubated for 1h with the primary

antibodies. Ultravision detection system (TP-015-HD) was used to complete immunostaining and Mayer's hematoxylin (TA-060-MH) was used for counterstaining. Citrate buffer, Ultravision detection system and Mayer's hematoxylin were purchased from Labvision Thermo Scientific, Fremont, California, USA.

Negative controls were done by applying same steps but omitting the step of adding the primary antibodies

Positive reaction appears as brown deposits in the extracellular matrix and in the cytoplasm for (MMPI) and as brown nuclear reaction for (PCNA).

### III) ADSCs isolation and culture:<sup>[22]</sup>

Isolation of ADSCs from rat abdominal subcutaneous fat and their culture and labeling with PKH26 and preparation of ADSC-CM, were performed at the Unit of Biochemistry and Molecular Biology at Medical Biochemistry Department, Faculty of Medicine, Cairo University, Egypt.

Abdominal subcutaneous fat were collected and transferred into tube with PBS. The tissue was minced into small pieces. The extracellular matrix was digested by adding collagenase solution then incubation at 37 °C for 40min was done. Collagenase was inactivated by adding DMEM into the 50 ml tube then centrifugation was done. The cell pellet was visible at the bottom of the tube. The supernatant was aspirated and the cell pellet was resuspended in 20 ml DMEM after centrifugation. The cell suspension was filtered and centrifugation was done. The cell pellet containing ADSCs was resuspended in 10 ml DMEM, transferred onto cell culture flask and incubated at 37 °C/5% CO<sub>2</sub> for 24 h. After that, the adherent cells (ADSCs) were washed with PBS and were cultured in fresh proliferation medium until 70% confluence. Subculture of ADSCs were done till the third passage to expand cell population. After several days of culture, ADSCs showed a typical fibroblastic-like morphology.

### Cell surface markers staining and flow cytometry:<sup>[22]</sup>

Isolated rat ADSCs were analyzed using the fluorescence activated cell sorter (FACS) hardware and software packages for data acquisition. Typically it was found that more than 98% of the isolated ADSCs express MSC markers, including CD90, CD44, CD29, CD73 and CD105. However, less than 1% of the isolated ADSCs express cell surface markers for hematopoietic cells (CD34, CD14, CD11b, and CD45) and markers for endothelial cells (CD31 and CD106).

ADSCs cells were harvested during the 3<sup>rd</sup> passage and were labeled with PKH26 fluorescent linker dye. according to Sigma protocol steps. After labeling with PKH26, undifferentiated ADSCs were injected intravenously into rat tail vein.

### VI) Adipose Stem Cell Conditioned Medium (ADSC-CM):

Rat ADSCs were seeded, and when they reached

confluence 70%, the medium was changed to a DMEM serum-free medium. The cells were exposed to 100 ng/mL rat IFN for a continuous 24 h to provide preconditioning of ADSCs for production of cytokines. After that, ADSCs were washed with PBS and were further incubated in serum free DMEM for 24 h. The conditioned media, which was designated as "culture CM after IFN stimulation" were collected, centrifuged at 3000g for 5 min, and finally filtered then further concentration was done<sup>[14]</sup>.

### Morphometric study

Ten non-overlapping fields from different sections of each rat of

each group were used to measure:

- Area percent of collagen (x400) .
- Number of goblet cells(x400)
- Optical density of alcian blue/PAS +ve reaction(x400)
- Area percent of MMP1(x400)
- Number of PCNA-positive cells. (x400)

Measurements were taken using "Leica Qwin 500 C" image analyzer computer system Ltd. (Cambridge, England). (Histology Department, Faculty of Medicine, Cairo University).

### Statistical analysis:

Quantitative data were summarized as means and standard deviations (SD) and compared using one-way analysis-of-variance (ANOVA) and followed by post hoc Tukey test. *P-values* <0.05 were considered statistically significant. Calculations were made on SPSS software version 21<sup>[23]</sup>.

## RESULTS:

### General observations:

No deaths were recorded in all rats during the experiment.

All control subgroups showed similar histological results so, they were collectively named control group.

On day 10, animals in group I (control group) showed increased body weight. While animals in groups II, III, IV, V and VI showed significant loss of body weight as compared to control group. On day 24, animals treated with ADSCs in group IV and ADSC-CM in group V showed significant increase in body weight compared to group III (recovery group) and VI (DMEM treated group) and non significant difference as compared to each other. (Table 1 and Histogram 1)

In experimental groups starting from day 6, the color of stools changed to black (indicating presence of blood). The stool frequency also increased from this time. In groups III and VI slight decrease in the stool frequency with minimal improvement of its color was noted by day 22. On the other

hand, animals of groups IV and V showed remarkable decrease in the stool frequency with obvious improvement in its color by day 17.

### **Histological results:**

- Fluorescence detection of PKH26 labeled ADSCs by fluorescent microscope:

Examination of PKH26-labelled ADSCs in unstained ileum sections revealed yellow fluorescence distributed within the villi (in the regenerated surface epithelium and CT corium), crypts as well as in the submucosa

- Hematoxylin and eosin stain: (Figs 1 and 2)

Examination of ileum sections from group I showed normal organization of villi and crypts, The epithelium covering the villi and lining the crypts was intact showing predominance of enterocytes with goblet cells scattered among them. The enterocytes appeared with its normal brush border. Continuous layer of muscularis mucosa with normal cellularity of the submucosa were also observed. Muscularis and adventitia appeared intact ( Fig. 1 A)

Sections from group II revealed obvious disorganization and damage of some villi and crypts together with desquamation of the epithelium covering the villi. Obvious mononuclear cellular infiltration in mucosa and submucosa was also observed. Wide spaces in villus core were noted in certain areas. Widening of the crypts with distortion of the cells lining the crypts were frequently seen (Figs. 1 B and C).

Groups III and VI revealed comparable results, ileum sections showed severe desquamation and damage of the epithelium covering the villi and severe destruction of the cells lining the crypts. Mononuclear cellular infiltration in both groups(Figs. 1d and f ). Mast cells in group III were detected in the villi core (Fig. 1E).

Meanwhile, groups IV and V showed remarkable improvement as most villi (Fig. 2 A and C) and crypts (Fig. 2 B and D) restored their architecture with normal distribution of enterocytes and goblet cells. However, mild mononuclear cellular infiltration of the lamina propria and wide spaces in the submucosa and in the CT core of few villi were still observed in group IV(Fig. 2 B).

- Masson's trichrome stain:(Fig. 3)

Examination of Masson's trichrome stained sections from group I showed fine collagen fibers in the CT core of villi and between the crypts. (Fig 3 A).

In group II, fine collagen fibers were seen in the lamina propria of the disrupted villi and in between the disorganized crypts (Fig. 3 B).

However, in groups III and VI obvious deposition of collagen in the lamina propria of the villi, in between the crypts and in the submucosa was detected (Fig 3 C and D). On the other hand, groups IV and V showed scattered collagen fibers in the lamina propria

of the villi core and in between the crypts(Fig. 3 E and F).

- Alcian blue /PAS stain:(Fig. 4)

Control group showed strong intensity of alcian blue /PAS reaction in the goblet cells and in the brush border of enterocytes(Fig 4 A). Groups II, III and VI showed few goblet cells with apparent weak intensity of the purple color of alcian blue/PAS stain in most of the fields. Lost brush border of most enterocytes was seen(Fig 4 B, C and D). On the other hand, groups IV and V showed numerous goblet cells with apparent strong intensity of purple color. The brush border of most enterocytes in villi and crypts was preserved and well-stained (Figs 4 E and F).

- MMP1 immunohistochemical stain:(Fig. 5)

Control group, The CT core of the villus showed localized faint brown positive extracellular reaction. Positive intracellular reaction was also seen(Fig 5 A). Groups II, III and VI showed widespread dense positive MMP1 expression in the extracellular matrix in wide areas of the mucosa together with strong positive cytoplasmic reaction in some enterocytes (Fig. 5 B, C and D). Meanwhile, groups IV and V showed localized weak positive MMP1 expression in the extracellular matrix of the mucosa and in the cytoplasm of some enterocytes and CT cells. (Fig 5 E and F).

- PCNA immunohistochemical stain: (Fig. 6)

Control group, showed positive nuclear immunoreactivity for PCNA in the villi core. Few enterocytes with positive immunoreactivity was also seen (Fig. 6 A). Groups II, III and VI revealed few PCNA +ve cells in the villi core (Fig 6 B, C and D) and in crypts lining epithelium (Fig 6 D). On the other hand, groups IV and V showed numerous PCNA +ve cells in the CT corium of the villi. Some enterocytes also showed positive immunoreactivity (Fig. 6 E and F).

### **Morphometric and statistical results (Table 2 and Histograms 2- 6):**

There was significant increase in the mean area % of collagen in groups III and VI compared to control group or to group II. On the other hand, groups IV and V showed significant reduction in the mean area percent of collagen when compared to groups III and VI and non significant difference when compared to each other.

There was significant decrease in the mean number of goblet cells and in the optical density of the mucus in groups II, III and VI compared to control group. On the other hand, groups IV and V showed significant increase as compared to groups II, III and VI and non significant difference when compared to each other or with the control group.

A significant increase in the mean area percent of MMP1 in groups II, III and VI was detected as compared to control group. However there was significant reduction in groups III and VI as compared to groups II. Also there

was significant reduction in groups IV and V as compared to groups II, III and VI and non significant difference when compared to each other.

The mean number of PCNA +ve cells in groups II, III


and VI showed significant reduction as compared to control group. On the other hand, groups IV and V showed significant increase as compared to groups II, III and VI. While group V showed significant increase as compared to group IV.

**Table 1:** The mean body weight in grams ( $\pm$  SD) of rats in the studied groups as recorded on day 0, 10 and 24

Group	Day 0	Day 10	Day 24
Group I (control group)	192.0 $\pm$ 1.0	215.3 $\pm$ 0.44	251.6 $\pm$ 2.2
Group II (Indomethacin induced enteritis)	192.0 $\pm$ 1.0	194.7 $\pm$ 0.74*	-
Group III (recovery group)	192.0 $\pm$ 1.0	194.7 $\pm$ 0.74*	168.5 $\pm$ 0.57 $\Omega$
Group IV (stem cell treated group)	192.0 $\pm$ 1.0	194.7 $\pm$ 0.74*	214.4 $\pm$ 1.5 $\Omega$
Group V (ADSC-CM-treated group)	192.0 $\pm$ 1.0	194.7 $\pm$ 0.74*	216.8 $\pm$ 1.8 $\Omega$
Group VI (DMEM-treated group)	192.0 $\pm$ 1.0	194.7 $\pm$ 0.74*	166.7 $\pm$ 1.2 $\Omega$

\*significant as compared to group I on day 10 ( $p < 0.05$ ).

$\Omega$  significant as compared to group I on day 24 ( $p < 0.05$ ).



**Histogram 1:** Mean body weight in grams of rats in the studied groups as recorded on day 0, 10 and 24.

\*significant as compared to group I on day 10 ( $p < 0.05$ ).

$\Omega$  significant as compared to group I on day 24 ( $p < 0.05$ ).

**Table 2:** Morphometric results


	Group I (control group)	Group II (indomethacin induced enteritis)	Group III (recovery group)	Group IV (stem cell treated group)	Group V (ADSC-CM-treated group)	Group VI (DMEM treated group)
Mean area % of collagen	0.08 $\pm$ 0.02	0.07 $\pm$ 0.01	1.70 $\pm$ 0.41 $\Delta$	0.1 $\pm$ 0.03 $\#$	0.09 $\pm$ 0.02 $\#$	1.38 $\pm$ 0.46 $\Delta$
Mean number of goblet cells/HPF ( $\pm$ SD)	46.10 $\pm$ 9.39	8.00 $\pm$ 2.00*	14.50 $\pm$ 3.62*	44.30 $\pm$ 13.07 $\Delta\#$	42.20 $\pm$ 8.63 $\Delta\#$	13.90 $\pm$ 3.84*
Mean optical density of alcian blue /PAS +ve reaction ( $\pm$ SD)	0.89 $\pm$ 0.05	0.72 $\pm$ 0.05*	0.70 $\pm$ 0.05*	0.85 $\pm$ 0.03 $\Delta\#$	0.83 $\pm$ 0.04 $\Delta\#$	0.67 $\pm$ 0.03*
Mean area % of MMP1 ( $\pm$ SD)	0.29 $\pm$ 0.08	10.33 $\pm$ 1.63*	8.41 $\pm$ 0.75 $\Delta$	0.84 $\pm$ 0.20 $\Delta\#$	0.62 $\pm$ 0.11 $\Delta\#$	7.96 $\pm$ 1.25 $\Delta$
Mean number of PCNA +ve cells/HPF ( $\pm$ SD)	36.4 $\pm$ 8.83	11.50 $\pm$ 3.02*	14.70 $\pm$ 4.42*	52.60 $\pm$ 10.84 $\Delta\#$	79.80 $\pm$ 17.86 $\Delta\#\#$	14.40 $\pm$ 4.35*

\* significant as compared to group I ( $p < 0.05$ ).

$\#$  significant as compared to group III and VI ( $p < 0.05$ ).

$\Delta$  significant as compared to group II ( $p < 0.05$ ).

$\#$  significant increase as compared to group IV ( $p < 0.05$ ).




**Histogram 2:** Mean area percent of collagen in the studied groups.

\* significant as compared to group I ( $p < 0.05$ )

Δ significant as compared to group II ( $p < 0.05$ )

# significant as compared to group III and VI ( $p < 0.05$ )




**Histogram 4:** Mean optical density of alcian blue/PAS +ve reaction in the studied groups

\* significant as compared to group I ( $p < 0.05$ )

Δ significant as compared to group II ( $p < 0.05$ )

# significant as compared to group III and VI ( $p < 0.05$ )




**Histogram 3:** Mean number of goblet cells/HPF in the studied groups

\* significant as compared to group I ( $p < 0.05$ )

Δ significant as compared to group II ( $p < 0.05$ )

# significant as compared to group III and VI ( $p < 0.05$ )




**Histogram 5:** Mean area percent of MMP1 in the studied groups

\* significant as compared to group I ( $p < 0.05$ )

Δ significant as compared to group II ( $p < 0.05$ )

# significant as compared to group III and VI ( $p < 0.05$ )




**Histogram 6:** Mean number of PCNA positive cells/HPF in the studied groups

\* significant as compared to group I ( $p < 0.05$ )


# significant as compared to group III and VI ( $p < 0.05$ )

Δ significant as compared to group II ( $p < 0.05$ )


¥ significant increase as compared to group IV ( $p < 0.05$ )




**Fig. 1:** A Photomicrograph of a section in the ileum of a rat stained with HandE (1A):control group showing normal villi (arrows) and crypts (C) with normal enterocytes (arrowhead) and goblet cells (G). Other layers appear normal (x200). (1B):group II showing disrupted villi with desquamation of the epithelial covering (doubled arrows). The crypts (C) showed widening and destruction of the cell lining. Mononuclear cellular infiltration (I) in mucosa and submucosa (x200). (1C): group II showing mononuclear cellular infiltration (I). Wide spaces in the core of the villi (stars) (x400). (1D):group III showing disrupted villi with desquamation of the epithelium covering (doubled arrows) with disorganized crypts (C) and mononuclear cellular infiltration (I) (x200). (1E):group III showing many mast cells (wavy arrows) (x1000). (1F):group VI showing severe destruction of the villi (green arrows) with desquamation of their covering epithelium (doubled arrow). The crypts (C) are deformed (x200).




**Fig. 2:** A Photomicrograph of a section in the ileum of a rat stained with HandE (2A): group IV, the villi (arrows) show normal architecture with normal distribution of enterocytes (arrowheads) and goblet cells (G) (x200). (2B): group IV, the villi (arrows) show normal architecture with normal distribution of enterocytes (arrowheads) and goblet cells (G). Well organized crypts (C) are also seen. Cellular infiltration (I) and some wide spaces (stars) are noted in the core of villi (x400). (2C):group V, the villi (arrows) show normal architecture with normal distribution of enterocytes (arrowheads) and goblet cells (G) and normal CT cellularity (square) (x200). (2D):group V, well organized crypts (C) with normal cell lining, goblet cells (G) and enterocytes (arrow head) (x400).




**Fig. 3:** A Photomicrograph of a section in the ileum of a rat stained with Masson's trichrome(3A): control group showing fine green stained collagen fibers in the villus core (arrow) and in between the crypts (wavy arrow). More dense collagen fibers are seen in submucosa (star)(x200).(3B):group II showing fine green stained collagen fibers in the lamina propria of disrupted villi (arrows) and in between the crypts (wavy arrows).More dense collagen fibers are seen in the submucosa (star) (x200). (3C):group III showing widespread green-stained dense thick collagen fibers in the lamina propriaof the villi (arrow) and in between the crypts (wavy arrows). Obvious deposition of collagen is seen in the submucosa (star)(x200).(3D):group V showing dense green-stained collagen bundles in the lamina propria of the villus core (arrow) and in between the crypts (wavy arrows). Deposition of collagen is seen in the submucosa (star)(x200).(3E):group IV showing scattered green-stained collagen fibers in the lamina propriaof the villi core (arrows) and in between the crypts (wavy arrow)More dense collagen is seen in the submucosa (star)(x200).(3F):group V, scattered green-stained collagen fibers in the lamina propriaof the villus core (arrow) and in between the crypts (wavy arrow). Note collagen fibers in the submucosa (star)(x200).



**Fig. 4:** A Photomicrograph of a section in the ileum of a rat stained with Alcain blue /PAS(4A):control group showing strong intensity of alcain blue /PAS reaction in the goblet cells (arrows) and in the brush border of enterocytes (arrowhead)(x200).(4B): group II showing apparently few goblet cells with apparent weak intensity of alcain blue /PAS stain (arrows). Lost brush border of most enterocytes (wavy arrows) but preserved well-stained brush border in few enterocytes are seen (arrowhead)(x200).(4C): group III, apparently few goblet cells in villi and crypts with apparent weak intensity of alcain blue/PAS stain (arrows). Brush borders of most enterocytes are lost (wavy arrow). Preserved well-stained brush borders are seen in few enterocytes (arrowhead)(x200).(4D): group VI, apparently few goblet cells; most of them exhibit apparent weak intensity of alcain blue/PAS stain (arrows). Only few enterocytes with preserved well-stained brush border are seen (arrowhead)(x200).(4E): group IV showing numerous goblet cells with an apparent strong intensity of alcain blue/PAS stain (arrows). The brush borders of most enterocytes are preserved and well-stained (arrowheads)(x200).(4F):group V, numerous goblet cells with apparent strong intensity of alcain blue/PAS stain(arrows). The brush border of most enterocytes is preserved and well-stained (arrowhead)(x200).



**Fig. 5:** A Photomicrograph of a section in the ileum of a rat stained with MMP1 immunostaining(5A): control group, The CT core of the villus shows localized faint brown positive extracellular reaction (arrow). Positive intracellular reaction can also be seen (arrowheads) (x400).(5B): group II showing widespread dense positive immunoreactivity for MMP1 in the extracellular matrix of the villi (arrows). Strong positive cytoplasmic reaction is also seen in some enterocytes (arrowhead) (x400).(5C): group III, The CT core of the villus shows widespread positive immunoreactivity for MMP1 in the extracellular matrix (arrows). Strong positive cytoplasmic reaction (arrowheads) is also detected in both enterocytes and CT cells (x400). (5D): group VI, disrupted villus with widespread positive immunoreactivity for MMP1 in the extracellular matrix (arrows) with some positive intracellular cytoplasmic reaction (arrowhead) (x400).(5E): group IV showing localized weak positive immunoreactivity for MMP1 in the extracellular matrix (arrow). Weak positive cytoplasmic reaction (arrowheads) in few enterocytes and CT cells is seen (x400).(5F): group V localized faint positive immunoreactivity for MMP1 in the extracellular matrix (arrow). Weak positive cytoplasmic reaction (arrowheads) is also seen in few enterocytes and CT cells (x400).



**Fig. 6:** A Photomicrograph of a section in the ileum of a rat stained with PCNA immunostaining(6A): control group, showing positive nuclear immunoreactivity for PCNA in the villi core (arrows). Few enterocytes with positive immunoreactivity are also seen (arrowhead) (x400).(6B) group II showing few cells with positive nuclear immunoreactivity for PCNA in a villus core (arrows) (x400).(6C): group III, the villus core show few cells with positive nuclear immunoreactivity for PCNA (arrows) (x400). (6D): group VI showing few cells with positive nuclear immunoreactivity for PCNA in the core of a disrupted villus (arrow) and in epithelial cells of the crypt (wavy arrow) (x400).(6E): group IV showing numerous cells in the villus core with positive nuclear immunoreactivity for PCNA (arrows). Some enterocytes with positive immunoreactivity are seen (arrowheads) (x400). (6F): group V numerous cells in the CT corium of a villus with positive nuclear immunoreactivity for PCNA (arrows). Some enterocytes with positive immunoreactivity are also seen (arrowheads) (x400).

## DISCUSSION

Crohn's disease is a debilitating lifelong IBD with significant health and economic costs<sup>[24]</sup>. The complications of this disease, such as stricturing and bowel fistula, account for substantial morbidity and health-care costs. Moreover, the validated models to predict complications and to evaluate the effect of the treatment are not available<sup>[25]</sup>.

The present work aimed to develop an experimental model of enteritis (Crohn's disease) using indomethacin in adult female albino rat. Female rats were used in this study as the small intestine of rat is more or less similar to that of human from histological point of view and the incidence of CD in the females is 1.5 times higher than males<sup>[26]</sup>.

In this study, ileum was chosen as it is the most common area of GIT affected in CD<sup>[27]</sup>. In addition, indomethacin was chosen for induction of a model of CD as it induced morphological and functional alterations in the small intestine similar to CD<sup>[28]</sup>.

In the current study, ADSCs were used, as these cells have the ability to differentiate into both mesodermal and non mesodermal lineages, similar to bone marrow-derived MSCs (BMSCs). However, ADSCs could be collected in large quantity with minimal morbidity. Moreover, the derivation of ADSCs is easier and less invasive and much more efficient than that of BMSCs. Thus, they are attractive stem cells for regenerative application<sup>[29,30]</sup>.

In the present work, the effect of ADSCs were evaluated after 2 weeks of administration according to a previous study which found that MSCs can colonize in the injured intestine and directly differentiate into mucosal epithelium cells after 14 days<sup>[13]</sup>.

It was mentioned that indomethacin was used to develop a model of enteritis. This model bears close resemblance to CD in terms of clinical and histopathological features<sup>[31]</sup> and carries in part, comparable pathogenesis<sup>[32,33]</sup>. This was obvious on examining the results of group II together with the possible explanations that correlate such model with CD.

In group II (indomethacin induced enteritis), HandE stained ileum sections showed findings that could be attributed to mucosal damage and to the inflammatory reaction following intake of indomethacin<sup>[34,35]</sup>. Similar histopathological features were described in CD<sup>[31]</sup>.

Tumor necrosis factor (TNF- $\alpha$ ) is a pro-inflammatory cytokine capable of upregulating its own expression as well as the expressions of other genes pivotal to the inflammatory response. Thus TNF- $\alpha$  plays a key role in the pathogenesis of indomethacin induced small intestinal injury<sup>[36]</sup> and the development and progression of IBD<sup>[33]</sup>.

HandE results of group III and group VI were comparable with each other. The findings of recovery group indicated progressive destruction of the intestinal mucosa with no spontaneous recovery till day 24 of the experiment. Also, the pathology in VI group was still present with no

noticeable improvement indicating that DMEM was a non effective treatment<sup>[37]</sup>.

The presence of many mast cells in the villus core of group III could be considered as a part of the inflammatory process that accompanied indomethacin treatment. It might induce prostaglandin deficiency that promotes the mucosal dysfunction and accumulation of inflammatory cells as neutrophils and mast cells, which express chymase enzyme and exacerbate inflammation<sup>[38]</sup>.

In the present work, examined ileum sections in all groups including the control group revealed positive cytoplasmic expression of MMP1. It was mentioned that MMP1 has low basal expression in most tissues and can be dynamically upregulated in response to cell activation<sup>[39]</sup>. In the current study groups II, III and VI showed significant increase in mean area % of MMP1 compared to control group. It was reported that the protein level of MMP1 was upregulated in IBD mucosa and in CD and its proteolytic activity was increased in the cells of inflamed epithelium. This elevation might be considered as a response to pro-inflammatory cytokines, such as IL-17A, IL-17F and IL-21 which cause upregulation of MMP1 in intestinal fibroblasts<sup>[40]</sup>. However, in the present work groups III and VI showed significant reduction in mean area % of MMP1 compared to group II. This might be due to fibrosis formed during the two weeks longer duration. Reduction in MMP1 and increase in tissue inhibitor of metalloproteinase-1 (TIMP-1) was previously detected in fibrosed areas of CD<sup>[41]</sup>.

In the current work, group II showed non significant decrease in the mean area % of collagen when compared to control group. This could be explained by loss of normally present collagen fibers with mucosal destruction. While there was significant increase in the mean area % of collagen in group III and VI when compared to group II. Indomethacin might induce fibrosis, as these groups were left for another two weeks or as an end stage of chronic inflammation<sup>[42]</sup>. Indomethacin could induce a chronic model of CD that associated with fibrosis, in such areas the TIMP-1 level was increased<sup>[43]</sup> and its expression was inversely correlated with inflammatory cytokine production and mucosal injury<sup>[41,44]</sup>. In the same consequence, increased expression of tissue transforming growth factor beta (TGF- $\beta$ ) in the inflamed intestine, led to increased TIMP-1 and decrease MMP1. TGF- $\beta$  activation is a central mediator of fibrosis<sup>[45]</sup>.

Groups II, III and VI, revealed significant reduction in the mean number of PCNA +ve cells compared to control group. This reduction could be explained by ulceration and loss of epithelial cells with destruction of villi and crypts. Similar decrease in PCNA positive cells and proliferative index was found in non-steroidal anti-inflammatory drugs (NSAIDs) induced enteritis model<sup>[46]</sup>. NSAIDs inhibit COX-2 and PGE2 production. This in turn decreases  $\beta$ -catenin protein signaling and decreasing transcription of proliferation genes in the intestines<sup>[47]</sup>.

In groups II, III and VI, there was significant reduction in the mean number of goblet cells compared to control group. This could be explained by ulceration of the mucosa and destruction of both villi and crypts by indomethacin. This finding was in accordance, with other authors who attributed this to enterobacterial invasion, upregulation of inducible nitric oxide synthase (iNOS) expression and overproduction of nitric oxide (NO) in the mucosa<sup>[48,49]</sup>. In addition, the present work revealed significant decrease in the mean optical density of the mucus in group II, III and VI compared to control group. This could be due to the altered mucus barrier and the increased expression of mucin 2 (MUC2), one of mucin family. This MUC2 has reduced oligosaccharide chain length by about 50% which lead to abnormal function of mucous barrier and play a role in the persistence of IBD<sup>[50]</sup>.

In the present work, animals treated with ADSCs in group IV and ADSCs-CM in group V showed significant increase in body weight on day 24 compared to group III and VI. Also stool frequency showed remarkable decrease with obvious improvement in its color on day 17. This difference could be attributed to the therapeutic effect of ADSCs and their conditioned medium respectively. In accordance with this findings, significant decrease in diarrhea and weight loss was recorded after intravenous injection of ADSCs for treatment of 2, 4, 6-Trinitrobenzene sulfonic acid (TNBS)-induced colitis in a murine experimental model of CD<sup>[51]</sup> and after intraperitoneal administration of BMSC-CM. for treatment of TNBS-induced colitis model<sup>[14]</sup>

Groups IV and V showed remarkable improvement as most villi and crypts restored their architecture with normal distribution of enterocytes and goblet cells. This could be attributed to the therapeutic effect of ADSCs that homed to the injured intestinal areas as detected by fluorescent microscope. Similarly, PKH26-labeled BMSCs relocated to and exhibited local proliferation and transdifferentiation into injured intestinal mucosal cells in a rat model of IBD<sup>[52]</sup>. Also local application of ADSCs resulted in perianal fistula closure rate in an animal model of CD<sup>[53]</sup>. MSCs could produce wound healing in TNBS induced colitis rat model through their production of a variety of humoral factors. Prostaglandin E2 (PGE2) is one of the humoral factor secreted from MSCs, It can repolarize pro-inflammatory M1 macrophages into anti-inflammatory M2 macrophages which become involved in inflammation resolution<sup>[54]</sup>. The efficacy of ADSCs has been recently reported in the small intestine of animal models of CD induced by TNBS<sup>[55]</sup>.

It was demonstrated that intraperitoneal administration of amniotic fluid MSC-CM ameliorated dextran sodium sulphate (DSS)-induced colitis in immunodeficient colitis mouse model<sup>[56]</sup>. The anti-inflammatory capacities of ADSC-CM was attributed to the presence of Extracellular vesicles (EVs) which could balance macrophage polarization toward the anti-inflammatory profile<sup>[57]</sup>. Recently, it was found that MSC-CM with its immunomodulatory properties has the potential to reduce inflammatory responses in a mouse model of IBD<sup>[6]</sup>.

Further enforcement came from PCNA immunostaining results of group IV which showed significant increase in the mean number of PCNA +ve cells when compared to control group, group II and recovery group. It was clarified that the transplanted PKH26-labeled BMSCs in rats subjected to experimental IBD showed a considerable extent of colocalization with PCNA, implicating that they undergo in situ proliferation in the gut<sup>[52]</sup>. However, other author attributed the increase in PCNA +ve cells to intestinal SCs homing to the injured intestinal areas as a response to factors produced in the inflamed tissues and its differentiation into epithelial and immune cells<sup>[58]</sup>.

Meanwhile, group V (ADSC-CM-treated group) showed numerous PCNA +ve cells in the villi and crypts with significant increase when compared to control group, group II and recovery group. In agreement with this result, it was found that the number of PCNA +ve cells was increased at 2 weeks, indicating that MSC-CM maintained a higher cellular activity and enhance early bone regeneration in rabbit model.<sup>[59]</sup>

On comparing both groups IV and V, group V showed significant increase in the number of PCNA +ve cells. This was explained by the presence of various growth factors like colony stimulating factors (CSF), such as granulocyte colony stimulating factor (G-CSF) granulocyte macrophage CSF (GM-CSF) which may recruit various resident stem cells including endothelial progenitors to the site of injury<sup>[60]</sup>.

The mean number of goblet cells and the mean optical density of mucus in groups IV and V exhibited significant increase when compared to groups II, III and VI. This could be attributed to ADSCs and their CM that improved the mucosal regeneration and reepithelialization and in turn improve goblet cell regeneration as a part of intestinal epithelium. The improvement of goblet cells might be due to various factors present in CM such as keratinocyte growth factor (KGF) that inhibits oxidative stress induced epithelial cell death<sup>[61]</sup>.

Significant decrease in the mean area % of MMP1 in groups IV and V when compared to groups II, III and VI. In ultra violet-irradiated human dermal fibroblasts, ADSCs reduced MMP1 expression leading to therapeutic benefit in the injured skin<sup>[62]</sup>. Also the reduction in MMP1 was referred to TIMP-1 present in MSC-CM stimulated with inflammatory cytokines<sup>[63]</sup>. Interestingly, the reduction in MMP1 in group V was comparable with that in group IV with no significant difference.

Groups IV and V showed significant decrease in the mean area % of collagen when compared to group III and non significant change when compared to control group. This could be referred to the anti-inflammatory ability of both ADSCs and their CM and to the restoration of the balance between MMP1 and TIMP-1. In the same concern, local injection of ADSCs in a rat model of TGF- $\beta$ 1 induced urethral fibrosis resulted in significant decrease in collagen type I and III<sup>[64]</sup>. Also, ADSCs had a favorable effect on

ECM regulation through suppression of TGF- $\beta$ 1 signaling in vocal fold fibroblasts during the co-culture of these cells with ADSCs<sup>[65]</sup>. The efficacy of MSCs in reducing the fibrosis might be secondary to reducing tissue damage<sup>[66]</sup>. The antifibrotic effect of ADSC-CM detected in the current work was in accordance with other study. In such study reduced scar formation was noticed after administration of amniotic MSC-CM. This occurred in bleomycin induced lung fibrosis animal model<sup>[67]</sup>. However, they didn't identify certain factors involved in the reduction of fibrosis. Later, the cytokine array of ADSC-CM was identified, including the presence of chemokines and growth factors (C-X-C) ligand 1 (CXCL1), chemokine ligand 3 (CCL3), TIMP-1 and Vascular endothelial growth factor (VEGF)), which promote chemotaxis and angiogenesis<sup>[68]</sup>.

Group V showed non significant difference in the mean area % of collagen when compared to group IV. Similarly non significant difference in fibrosis score between the CM-treated group and the MSC-treated group was found in a rat model of Cisplatin-induced kidney injury<sup>[69]</sup>.

Therefore, the present work revealed that ADSCs and their CM are apparently equal in their efficacy. Similarly, MSC-CM was sufficient to improve multiple biomarkers of pathophysiology and to be as effective as transplantation of the corresponding MSCs in a long list of animal models<sup>[70]</sup>.

However, in the applied regenerative medicine, MSC-CM could be superior and more promising than MSCs. It has several advantages including, higher biosafety as its administration has fewer risks of tumor formation. In addition, it has immediate availability as it can be stored, while living cells require extensive time for expansion. Also, it has easier, safer handling and requires less complex medical facilities. Finally, it has lower production costs, since the MSC secretome can be produced in large quantities<sup>[71]</sup>.

## CONCLUSION

1. Two SC doses of indomethacin was effective to induce a rat model of chronic enteritis (Crohn's disease).
2. The ADSCs could reduce tissue damage and fibrosis and enhance proliferation in the intestinal tissues in a rat model of enteritis.
3. The ADSC-CM was as effective as the transplantation of its corresponding ADSCs in mucosal regeneration, this might provide a hope for cell free therapy in degenerative diseases as a new therapeutic strategy.

## CONFLICT OF INTEREST:

There are no conflicts of interest.

## REFERENCES

1. Kanizaj TF and Mijic M (2017): Inflammatory bowel disease in liver transplanted patients. *World J Gastroenterol*; 23(18): 3214-3227.
2. Chen YL, Chen YT, Lo CF, Hsieh CI, Chiu SY, Wu CY, YehYS, Hung SH, Cheng PH, Su YH, Jiang ST, Chin HJ and Su YC (2016): Early detection of T cell transfer-induced autoimmune colitis by in vivo imaging system. *Sci Rep*; 6: 35635-35647.
3. Hakim GD, Soyuturk M, Unlu M, Ataca P, Karaman M, Sagol O, Borekci E, and Yilmaz O (2015): Mucosal healing effect of nilotinib in indomethacin-induced enterocolitis: a rat model. *World J Gastroenterol*; 21(44): 12576-12585.
4. Engels M, Cross RK and Long MD(2017): Exercise in patients with inflammatory bowel diseases: current perspectives. *Clin Exp Gastroenterol*; 11:1-11.
5. Su J, Xie C, Fan Y, Cheng W, Hu Y, Huang Q, Shi H, Wang L and Ren J (2017): Interleukin- 25 enhances the capacity of mesenchymal stem cells to induce intestinal epithelial cell regeneration. *Am J Transl Res*; 9(12): 5320-5331.
6. Pouya S, Heidari M, Baghaei K, Asadzadeh Aghdaei H, Moradi A, Namaki S, Zali MR and Hashemi SM (2018): Study the effects of mesenchymal stem cell conditioned medium injection in mouse model of acute colitis. *Int Immunop-harmacol*; 54: 86-94.
7. García-Arranz M, Herreros MD, González-Gómez C, de la Quintana P, Guadalajara H, Georgiev-Hristov T, Trébol J and García-Olmo D(2016): Treatment of Crohn's-related rectovaginal fistula with allogeneic expanded- adipose derived stem cells: a phase I-IIa clinical trial. *Stem Cells Transl Med*; 5(11):1441-1446.
8. Volarevic V, Markovic BS, Gazdic M, Volarevic A, Jovicic N, Arsenijevic N, Armstrong L, Djonov V, Lako M and Stojkovic M (2018): Ethical and safety issues of stem cell-based therapy. *Int J Med Sci*; 15(1):36-45.
9. Jiao X, Cai J, Yu X and Ding X (2017): Paracrine activation of the Wnt/ $\beta$ -catenin pathway by bone marrow stem cell attenuates cisplatin-induced kidney injury. *Cell Physiol Biochem*; 44(5): 1980-1994.
10. Liu B, Ding F, Hu D, Zhou Y, Long C, Shen L, Zhang Y, Zhang D and Wei G (2018): Human umbilical cord mesenchymal stem cell conditioned medium attenuates renal fibrosis by reducing inflammation and epithelial-to-mesenchymal transition via the TLR4/NF- $\kappa$ B signaling pathway in vivo and in vitro. *Stem Cell Res Ther*; 9(1):7-20.

11. Pawar AT, Anap RM, Ghodasara JV and Kuchekar BS (2011): Protective effect of hydroalcoholic root extract of *Rubiaceae cordifolia* in indomethacin-induced enterocolitis in rats. *Indian J Pharm Sci*; 73(2): 250-253.
12. Gonçalves Fda C, Schneider N, Pinto FO, Meyer FS, Visioli F, Pfaffenseller B, Lopez PL, Passos EP, Cirne-Lima EO, Meurer L and Paz AH (2014): Intravenous vs intraperitoneal mesenchymal stem cells administration: What is the best route for treating experimental colitis? *World J Gastroenterol*; 20(48): 18228-18239.
13. Sun T, Gao GZ, Li RF, Li X, Li DW, Wu SS, Yeo AE and Jin B (2015a): Bone marrow-derived mesenchymal stem cell transplantation ameliorates oxidative stress and restores intestinal mucosal permeability in chemically induced colitis in mice. *Am J Transl Res*; 7(5): 891-901.
14. Watanabe S, Arimura Y, Nagaishi K, Isshiki H, Onodera K, Nasuno M, Yamashita K, Idogawa M, Naishiro Y, Murata M, Adachi Y, Fujimiya M, Imai K and Shinomura Y (2014): Conditioned mesenchymal stem cells produce pleiotropic gut trophic factors. *J Gastroenterol*; 49(2): 270-282.
15. El-Akabawy G, El-Kholy W (2014): Neuroprotective effect of ginger in the brain of streptozotocin-induced diabetic rats. *Ann Anat*; 169: 119-128.
16. Zhang J, Zhi W, Tan M, Chen X, Li X and Deng L (2010): An experimental study on rabbit bone marrow mesenchymal stem cells double-labeled by PKH26 and 5-bromo-2'-deoxyuridine in vitro and application in cardiac patch. *Zhongguo Xue Bao*; 24(7): 828-833. (English abstract).
17. Kiernan JA (2001): *Histological and Histochemical methods: Theory and Practice*, 3rd ed., Arnold publisher, London, New York and New Delhi, 111-162 and 219-240.
18. Bancroft JD and Gamble M (2008): *Connective tissues and stains*. In: *Theory and Practice of Histological Techniques*, 6th ed., Elsevier Health Sciences, Churchill Livingstone, Edinburgh, London, Oxford, New York, Philadelphia, St Louis, Sydney and Toronto, 135-160.
19. Suvarna KS, Layton C and Bancroft JD (2012): *Immunohistochemical techniques*. In: *Bancroft's theory and Practice of histological techniques*, 7th ed., Elsevier Health Science, China, 381-426.
20. Giuffrida P, Biancheri P and MacDonald TT (2014): Proteases and small intestinal barrier function in health and disease. *Curr Opin Gastroenterol*; 30(2): 147-153.
21. Naryzhny SN (2008): Proliferating cell nuclear antigen: a proteomics view. *Cell Mol Life Sci*; 65(23): 3789-3808.
22. Ge X, Leow SC, Sathiakumar D, Stunkel W, Shabbir A, So JB, Lomanto D and McFarlane C (2016): Isolation and culture of human adipose-derived stem cells from subcutaneous and visceral white adipose tissue compartments. *Bio-protocol*; 6(22): e2027-e2037.
23. Emsley R, Dunn G and White IR (2010): Mediation and moderation of treatment effects in randomized controlled trials of complex interventions. *Stat Methods Med Res*; 19(3): 237-270.
24. Swarup N, Nayak S, Lee J, Pai Raikar S, Hou D, Sockalingam S and Lee KJ (2017): Forming a support group for people affected by inflammatory bowel disease. *Patient Prefer Adherence*; 11: 277-281.
25. Kugathasan S, Denson LA, Walters TD, Kim MO, Marigorta UM, Schirmer M, Mondal K, Liu C, Griffiths A, Noe JD, Crandall WV, Snapper S, Rabizadeh S, Rosh JR, Shapiro JM, Guthery S, Mack DR, Kellermayer R, Kappelman MD, Steiner S, Moulton DE, Keljo D, Cohen S, Oliva-Hemker M, Heyman MB, Otley AR, Baker SS, Evans JS, Kirschner BS, Patel AS, Ziring D, Trapnell BC, Sylvester FA, Stephens MC, Baldassano RN, Markowitz JF, Cho J, Xavier RJ, Huttenhower C, Aronow BJ, Gibson G, Hyams JS and Dubinsky MC (2017): Prediction of complicated disease course for children newly diagnosed with Crohn's disease: a multicentre inception cohort study. *Lancet*; 389(10080): 1710-1718.
26. Law ST and Li KK (2014): Gender-related differences in clinical course of Crohn's disease in an Asian population: a retrospective cohort review. *Arq Gastroenterol*; 51(2): 90-96.
27. Goulart RA, Barbalho SM, Gasparini RG and de Carvalho AC (2016): Facing terminal ileitis: going beyond Crohn's disease. *Gastroenterology Res*; 9(1): 1-9.
28. Simon H, Fischer T, Almási A and Fischer E (2017): Effects of mesalazine on morphological and functional changes in the indomethacin-induced inflammatory bowel disease (rat model of Crohn's disease). *Pathol Oncol Res*; 23(1): 41-46.
29. Uzbas F, May ID, Parisi AM, Thompson SK, Kaya A, Perkins AD and Memili E (2015): Molecular physiognomies and applications of adipose-derived stem cells. *Stem Cell Rev*; 11(2): 298-308.
30. Zhang F, Ren H, Shao X, Zhuang C, Chen Y and Qi N (2017): Preservation media, durations and cell concentrations of short-term storage affect key features of human adipose-derived mesenchymal

- stem cells for therapeutic application. *PeerJ*; 5: e3301-3322.
31. Shah MK, Wan J, Janyaro H, Tahir AH, Cui L and Ding MX (2016): Visceral hypersensitivity is provoked by 2,4,6-trinitrobenzene sulfonic acid-induced ileitis in rats. *Front Pharmacol*; 7: 214-226.
  32. Michielan A and D'Inca R (2015): Intestinal permeability in inflammatory bowel disease: pathogenesis, clinical evaluation, and therapy of leaky gut. *Mediators Inflamm*; 2015: 628157 - 628166.
  33. Lew D, Yoon SM, Yan X, Robbins L, Haritunians T, Liu Z, Li D and McGovern DP (2017): Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients. *World J Gastroenterol*; 23(40): 7265 - 7273.
  34. Yamamoto A, Itoh T, Nasu R and Nishida R(2014): Sodium alginate ameliorates indomethacin-induced gastrointestinal mucosal injury via inhibiting translocation in rats. *World J Gastroenterol*; 20(10): 2641-2652.
  35. Lichtenberger LM, Bhattarai D, Phan TM, Dial EJ and Uray K (2015): Suppression of contractile activity in the small intestine by indomethacin and omeprazole. *Am J Physiol Gastrointest Liver Physiol*; 308(9): G785-793.
  36. Fukumoto K, Naito Y, Takagi T, Yamada S, Horie R, Inoue K, Harusato A, Hirata I, Omatsu T, Mizushima K, Hirai Y, Yoshida N, Uchiyama K, Ishikawa T, Handa O, Konishi H, Wakabayashi N, Yagi N, Kokura S, Ichikawa H, Kita M and Yoshikawa T (2011): Role of tumor necrosis factor- $\alpha$  in the pathogenesis of indomethacin-induced small intestinal injury in mice. *Int J Mol Med*; 27(3): 353- 359.
  37. Li N, Wang P, Ma XL, Wang J, Zhao LJ, Du L, Wang LY, Wang XR and Liu KD(2014): Effect of bone marrow stromal cell transplantation on neurologic function and expression of VEGF in rats with focal cerebral ischemia. *Mol Med Rep*; 10(5): 2299–2305.
  38. Kakimoto K, Takai S, Murano M, Ishida K, Yoda Y, Inoue T, Jin D, Umegaki E and Higuchi K (2010): Significance of chymase-dependent matrix metalloproteinase-9 activation on indomethacin-induced small intestinal damages in rats. *J PharmacolExpTher*; 332(2): 684-689.
  39. Foley CJ and Kuliopulos A(2014): A mouse matrix metalloprotease-1a (Mmp1a) gives new insight into MMP function. *J Cell Physiol*; 229(12): 1875–1880.
  40. O'Sullivan S, Gilmer JF and Medina C (2015):Matrix metalloproteinases in inflammatory bowel disease: an update. *Mediators Inflamm*; 2015: 964131- 964149.
  41. Latella G, Rogler G, Bamias G, Breynaert C, Florholmen J, Pellino G, Reif S, Specia S and Lawrance IC (2014): Results of the 4th scientific workshop of the ECCO (I): pathophysiology of intestinal fibrosis in IBD. *J Crohns Colitis*; 8(10): 1147-1165.
  42. Wynn TA and Ramalingam TR (2012): Mechanisms of fibrosis: therapeutic translation for fibrotic disease. *Nat Med*; 18(7): 1028–1040.
  43. Kawada M, Arihiro A and Mizoguchi E (2007): Insights from advances in research of chemically induced experimental models of human inflammatory bowel disease. *World J Gastroenterol*; 13(42): 5581-5593.
  44. Rogler G and Hausmann M (2017): Factors promoting development of fibrosis in Crohn's disease. *Front Med (Lausanne)*; 4: 96-101.
  45. Latella G, Sferra R, Specia S, Vetuschi S and Gaudio E (2013): Can we prevent, reduce or reverse intestinal fibrosis in IBD ? *Eur Rev Med PharmacolSci*; 17(10) : 1283 –1304.
  46. Lai Y, Zhong W, Yu T, Xia ZS, Li JY, Ouyang H, Shan TD, Yang HS and Chen QK (2015):Rebamipide promotes the regeneration of aspirin-induced small-intestine mucosal injury through accumulation of  $\beta$ -Catenin. *PLoS One*; 10(7): e0132031- 0132048.
  47. Castellone MD, Teramoto H and Gutkind JS (2006): Cyclooxygenase-2 and colorectal cancer chemoprevention: the beta-catenin connection. *Cancer Res*; 66(23): 11085–11088.
  48. Hayashi S, Kurata N, Yamaguchi A, Amagase K and Takeuchi K (2014):Lubiprostone prevents nonsteroidal anti-inflammatory drug-induced small intestinal damage by suppressing the expression of inflammatory mediators via EP4 receptors. *J PharmacolExpTher*; 349(3): 470- 479.
  49. Takeuchi K, Abe N and Kumano A (2016): Influence of adrenalectomy on protective effects of Urocortin I, a corticotropin-releasing factor, against indomethacin-induced enteropathy in rats. *CurrNeuropharmacol*; 14(8): 866-875.
  50. Cornick S, Tawiah A and Chadee K (2015): Roles and regulation of the mucus barrier in the gut. *Tissue Barriers*; 3(1-2): e982426- e982440.
  51. González MA, Gonzalez-Rey E, Rico L, Büscher D and Delgado M(2009): Adipose-derived mesenchymal stem cells alleviate experimental colitis by inhibiting inflammatory and autoimmune

- responses. *Gastroenterology*; 136(3):978-989.
52. Qu B, Xin GR, Zhao LX, Xing H, Lian LY, Jiang HY, Tong JZ, Wang BB and Jin SZ (2014): Testing stem cell therapy in a rat model of inflammatory bowel disease: role of bone marrow stem cells and stem cell factor in mucosal regeneration. *PLoS One*; 9(10): e107891-107900.
  53. Ryska O, Serclova Z, Meřtak O, Matouskova E, Vesely P and Mrazova I(2017): Local application of adipose-derived mesenchymal stem cells supports the healing of fistula: prospective randomised study on rat model of fistulising Crohn's disease. *Scand J Gastroenterol*; 52(5): 543-550.
  54. Miyamoto S, Ohnishi S, Onishi R, Tsuchiya I, Hosono H, Katsurada T, Yamahara K, Takeda H and Sakamoto N (2017): Therapeutic effects of human amnion-derived mesenchymal stem cell transplantation and conditioned medium enema in rats with trinitrobenzene sulfonic acid-induced colitis. *Am J Transl Res*; 9(3): 940-952.
  55. Xie M, Qin H, Luo Q, He X, He X, Lan P and Lian L (2017): Comparison of adipose-derived and bone marrow mesenchymal stromal cells in a murine model of Crohn's disease. *Dig Dis Sci*; 62(1): 115–123.
  56. Legaki E, Roubelakis MG, Theodoropoulos GE, Lazaris A, Kollia A, Karamanolis G, Marinos E and Gazouli M (2016): Therapeutic potential of secreted molecules derived from human amniotic fluid mesenchymal stem/stroma cells in a mice model of colitis. *Stem Cell Rev*;12(5): 604-612.
  57. Lo Sicco C, Reverberi D, Balbi C, Ulivi V, Principi E, Pascucci L, Becherini P, Bosco MC, Varesio L, Franzin C, Pozzobon M, Cancedda R and Tasso R (2017): Mesenchymal stem cell-derived extracellular vesicles as mediators of anti-inflammatory effects: endorsement of macrophage polarization. *Stem Cells Transl Med*; 6(3): 1018-1028.
  58. De Francesco F, Romano M, Zarantonello L, Ruffolo C, Neri D, Bassi N, Giordano A, Zanusi G, Ferraro GA and Cillo U(2016): The role of adipose stem cells in inflammatory bowel disease: from biology to novel therapeutic strategies. *Cancer Biol Ther*; 17(9): 889-898.
  59. Katagiri W, Osugi M, Kinoshita K and Hibi H (2015): Conditioned medium from mesenchymal stem cells enhances early bone regeneration after maxillary sinus floor elevation in rabbits. *Implant Dent*; 24(6): 657-63.
  60. Kim J, Lee JH, Yeo SM, Chung HM and Chae JI (2014): Stem cell recruitment factors secreted from cord blood-derived stem cells that are not secreted from mature endothelial cells enhance wound healing. *In Vitro Cell Dev Biol Anim*; 50(2): 146–154.
  61. Pawitan JA (2014): Prospect of stem cell conditioned medium in regenerative medicine. *Biomed Res Int*; 2014: 965849-965852.
  62. Son WC, Yun JW and Kim BH (2015): Adipose-derived mesenchymal stem cells reduce MMP-1 expression in UV-irradiated human dermal fibroblasts: therapeutic potential in skin wrinkling. *Biosci Biotechnol Biochem*; 79(6): 919-25.
  63. Zanotti L, Angioni R, Cali B, Soldani C, Ploia C, Moalli F, Garghesha M, D'Amico G, Elliman S, Tedeschi G, Maffioli E, Negri A, Zacchigna S, Sarukhan A, Stein JV and Viola A (2016): Mouse mesenchymal stem cells inhibit high endothelial cell activation and lymphocyte homing to lymph nodes by releasing TIMP-1. *Leukemia*; 30(5): 1143-1154.
  64. Sangkum P, Yafi FA, Kim H, Bouljihad M, Ranjan M, Datta A, Mandava SH, Sikka SC, Abdel-Mageed AB and Hellstrom WJ (2016): Effect of adipose tissue-derived stem cell injection in a rat model of urethral fibrosis. *Can Urol Assoc J*; 10(5-6): E175-E180.
  65. Hiwatashi N, Bing R, Kraja I and Branski RC(2017): Mesenchymal stem cells have antifibrotic effects on transforming growth factor- $\beta$ 1-stimulated vocal fold fibroblasts. *Laryngoscope*; 127(1): E35-E41.
  66. Li L, Zhang S, Zhang Y, Yu B, Xu Y and Guan Z (2009): Paracrine action mediate the antifibrotic effect of transplanted mesenchymal stem cells in a rat model of global heart failure. *Mol Biol Rep*; 36(4): 725-731.
  67. Cargnoni A, Ressel L, Rossi D, Poli A, Arienti D, Lombardi G and Parolini O (2012): Conditioned medium from amniotic mesenchymal tissue cells reduces progression of bleomycin-induced lung fibrosis. *Cytotherapy*; 14(2): 153–161.
  68. Rathinasabapathy A, Bruce E, Espejo A, Horowitz A, Sudhan DR, Nair A, Guzzo D, Francis J, Raizada MK, Shenoy V and Katovich MJ (2016): Therapeutic potential of adipose stem cell-derived conditioned medium against pulmonary hypertension and lung fibrosis. *Br J Pharmacol*; 173(19): 2859-2879.
  69. Abouelkheir M, ElTantawy DA, Saad MA, Abdelrahman KM, Sobh MA, Lotfy A and Sobh M (2016): Mesenchymal stem cells versus their conditioned medium in the treatment of cisplatin-induced acute kidney injury: evaluation of efficacy and cellular side effects. *Int J Clin Exp Med*; 9(12): 23222-23234.

70. Vizoso FJ, Eiro N, Cid S, Schneider J andPerez-Fernandez R(2017): Mesenchymal stem cell secretome: toward cell-free therapeutic strategies in regenerative medicine. *Int J MolSci*; 18(9): E1852-1875.
71. Oses C, Olivares B, Ezquer M, Acoŝta C, Bosch P, Donoso M, Léniz P and Ezquer F(2017):

Preconditioning of adipose tissue-derived mesenchymal stem cells with deferoxamine increases the production of pro-angiogenic, neuroprotective and anti-inflammatory factors: Potential application in the treatment of diabetic neuropathy. *PLoS One*; 12(5): e0178011-0178032.

## الملخص العربي

دراسة هستولوجية مقارنة علي تأثير الخلايا الجذعية المستخلصة من النسيج الدهني مقابل الوسط المكيف لها في التهاب الأمعاء الدقيقة المستحث تجريبيا بالإندوميثاسين في إناث الجرذان البيضاء البالغة

عبير فؤاد عبد المحسن<sup>1</sup>, نجلاء محمد سلامة<sup>1</sup>, ليلى احمد راشد<sup>2</sup>, ايمان عباس فرج<sup>1</sup>,  
اسماء محمد عبد الحميد<sup>1</sup>

<sup>1</sup> قسم الهستولوجيا، <sup>2</sup> قسم الكيمياء الحيوية، كلية الطب، جامعه القاهرة، مصر.

**الخلفية:** مرض التهاب الأمعاء ، بما في ذلك مرض كرون هو التهاب مناعي مزمن مركب ذو انتشار متزايد وعدم كفاية العلاج التقليدي.

**الهدف من العمل:** تقييم التأثير العلاجي للخلايا الجذعية المستخلصة من النسيج الدهني مقابل الوسط المكيف لها في نموذج التهاب الأمعاء الدقيقة في الجرذ.

**المواد والطرق:** تم استخدام ست وخمسين أنثى من الجرذان البيضاء ، 16 منها استخدموا كمجموعة ضابطة (المجموعة الأولى). والجرذان الأربعة المتبقية تم حقنها بجرعتين من الإندوميثاسين 7.5 مجم / كجم تحت الجلد ، في الأيام 0 و 1 من التجربة. وبعد 10 أيام تم تقسيم الفئران بالتساوي إلى 5 مجموعات: لم تحصل المجموعة الثانية والثالثة على أي علاج إضافي وتمت التضحية في الأيام 10 و 24 على التوالي. في حين تم حقن المجموعة الرابعة والسادسة بمليون من الخلايا الجذعية المستخلصة من النسيج الدهني ، جرعة واحدة في الوريد والوسط المكيف للخلايا بعد إثارها بالجاما انترفيرون بمقدار 0.5 مل داخل الغشاء البريتوني 5 جرعات و دولبيكو المعدل لوسط إيجل بمقدار 0.5 مل 5 جرعات على التوالي. تم التضحية بجميع الجرذان في اليوم الرابع والعشرين. تم صبغ عينات اللفائفي باستخدام صبغة الهيماتوكسيلين والايوسين و صبغه ماسون ثلاثي الألوان صبغه ألشيان الأزرق / حمض شيف الأيودي وكذلك صبغه هستوكيميائية مناعية للانزيم المحلل للميتالوبروتين 1 والمستضد النووي لتكاثر الخلايا. تم اخذ القياسات المورفومترية للنسبة المئوية لمساحة الكولاجين، وعدد الخلايا الكأسية والكثافة البصرية لتفاعل ألشيان الأزرق / حمض شيف الأيودي والنسبة المئوية لمساحة التفاعل المناعي للانزيم المحلل للميتالوبروتين 1 وعدد الخلايا الإيجابية للتفاعل المناعي للمستضد النووي لتكاثر الخلايا وقد تم تحليل البيانات إحصائيا.

**النتائج:** كشفت المجموعات الثانية والثالثة والسادسة عن اضطراب واضح وتلف في الخملات والأخاديد مع سقوط الغشاء المخاطي المغطي للخملات أيضا تسلل خلايا أحادية النواة في الغشاء المخاطي والتحت المخاطي جنبا إلى جنب مع انخفاض كبير ذو دلالة احصائية في عدد الخلايا الكأسية و الخلايا الإيجابية للمستضد النووي لتكاثر الخلايا وكذلك في الكثافة البصرية للمخاط وزيادة كبيرة ذات دلالة احصائية في النسبة المئوية لمساحة الكولاجين (في المجموعتين الثالثة والسادسة) و الانزيم المكسر للميتالوبروتين 1 بالمقارنة مع المجموعة الضابطة. استعادت المجموعتان الرابعة والخامسة تقريبا التركيب النسيجي الطبيعي للخملات والأخاديد.

**الخلاصة:** لقد كان استخدام الوسط المكيف للخلايا الجذعية المستخلصة من النسيج الدهني فعالا مثل استخدام الخلايا الجذعية المستخلصة من النسيج الدهني في الحد من تليف الأنسجة وفي تعزيز الانتشار وتجديد الغشاء المخاطي في نموذج التهاب الأمعاء الدقيقة (مرض كرون).

**الكلمات الدالة:** الإندوميثاسين ، التهاب الأمعاء الدقيقة ، مرض كرون ، الخلايا الجذعية المستخلصة من النسيج الدهني، الوسط المكيف